Neeraj Agarwal, MD, on Advanced Prostate Cancer: Data on Cabozantinib Plus Atezolizumab

October 15, 2021 By The ASCO Post Staff

Neeraj Agarwal, MD, of Hunstman Cancer Institute at the University of Utah, discusses efficacy and safety results from the COSMIC-021 study, in which cabozantinib plus atezolizumab demonstrated clinically meaningful activity and a manageable safety profile in patients with metastatic castration-resistant prostate cancer. The findings support a phase III study of these agents vs a second line of novel hormonal therapy (Abstract LBA24).

Related Content